Provided by Tiger Trade Technology Pte. Ltd.

Provident

21.01
+0.08000.38%
Volume:16.58K
Turnover:348.37K
Market Cap:2.74B
PE:10.71
High:21.05
Open:21.04
Low:20.95
Close:20.93
52wk High:21.29
52wk Low:14.34
Shares:130.62M
Float Shares:126.13M
Volume Ratio:0.20
T/O Rate:0.01%
Dividend:0.96
Dividend Rate:4.57%
EPS(TTM):1.96
EPS(LYR):1.05
ROE:9.51%
ROA:1.05%
PB:0.99
PE(LYR):19.94

Loading ...

Cal-Maine Foods And 2 Top Dividend Stocks To Enhance Your Portfolio

Simply Wall St.
·
Dec 06

Press Release: Emerita Awards Pre-Feasibility Study Contract for the Iberian Belt West Project to SLR Consulting

Dow Jones
·
Dec 03

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

GlobeNewswire
·
Dec 03

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

GlobeNewswire
·
Dec 02

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

GlobeNewswire
·
Dec 02

3 Reliable Dividend Stocks To Consider With Up To 9.9% Yield

Simply Wall St.
·
Dec 02

3 Dividend Stocks To Consider With Up To 3.6% Yield

Simply Wall St.
·
Nov 27

Provident Bank and The Provident Bank Foundation Launch Crisis Response Fund to Address Food Insecurity

GlobeNewswire
·
Nov 26

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

GlobeNewswire
·
Nov 25

Press Release: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Nov 24

ASX Runners of the Week: Alvo, 3D Energi, Zuleika & McLaren

The West Australian
·
Nov 21

Top Three Dividend Stocks To Consider For Your Portfolio

Simply Wall St.
·
Nov 21

Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer

Benzinga
·
Nov 19

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

GlobeNewswire
·
Nov 19

Press Release: Immatics Announces Third Quarter 2025 Financial Results and Business Update

Dow Jones
·
Nov 17

3 Dividend Stocks You Should Know With Yields Up To 9.7%

Simply Wall St.
·
Nov 17

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

GlobeNewswire
·
Nov 17

Press Release: IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Dow Jones
·
Nov 14

Press Release: The Metals Company Announces Third Quarter 2025 Corporate Update

Dow Jones
·
Nov 14

2025 AGM Chairman’s Address

GlobeNewswire
·
Nov 13